Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 58 resultados

INTERACT: Interdisciplinary Marie Sk odowska Curie Action for Health INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un HORIZON EUROPE: HORIZON-MSCA-2023-COFUND-01 The last decades are characterised by great breakthroughs in the understanding, diagnosing, and treating of many diseases. As fields advance...
2024-09-13 - 2030-08-31 | Financiado

Adaptmet: Deconstructing adaptive evolution of metastasis Adaptmet aims to develop an advanced training program encompassing the multifaceted aspects of metastasis adaptation mechanisms, intending t...
2024-07-05 - 2029-02-28 | Financiado

Evomet: Deconstructing the evolution of metastasis INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-MSCA-ITN-2020 Evomet aims to create a high-level training programme on the various aspects of metastasis evolution in order to provide young researchers w...
2020-09-03 - 2025-02-28 | Financiado

VAGABOND: Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate students INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-MSCA-ITN-2020 Pre-clinical drug development for paediatric cancers is very complex, resource intensive and requiring multi-disciplinary expertise and inno...
2020-08-18 - 2024-11-30 | Financiado

UBIMOTIF: Short linear interaction motifs as specificity determinants in the ubiquitin system discovery mec... INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-MSCA-ITN-2019 A major challenge is the lack of therapeutic approaches for numerous human diseases, which poses a societal challenge. The ubiquitin system...
2019-08-09 - 2024-05-31 | Financiado

EVOMET: The rise and fall of metastatic clones under immune attack INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG tramitó un H2020: H2020-MSCA-IF-2018 Colorectal cancer is the second most common cancer in Europe, and although screening has drastically increased survival, a fraction of patie...
2019-03-19 - 2021-08-07 | Financiado

CANCEREVO: Deciphering and predicting the evolution of cancer cell populations INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: ERC-2018-COG The fundamental evolutionary nature of cancer is well recognized but an understanding of the dynamic evolutionary changes occurring througho...
2019-01-23 - 2025-03-31 | Financiado

FURTHER: Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone... INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-SC1-BHC-2018-2020 "Bone metastases are a common manifestation of advanced cancer, with pain as a devastating consequence. Due to rising cancer incidence rates...
2018-12-05 - 2025-12-31 | Financiado

UCOM: Ultrasound Cavitation in Soft Materials INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-MSCA-ITN-2018 The pressures and temperatures developing during the interactions of shockwaves with cavitation bubbles and soft matter induce complex pheno...
2018-08-20 - 2023-05-31 | Financiado

COLOSSUS: Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer Systems based patient stra... INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-SC1-2016-2017 Colorectal cancer (CRC) is the third most common cancer in Europe with c. 420,000 cases and 150,000 related deaths in 2012. Of total CRC cas...
2017-11-21 - 2023-06-30 | Financiado

CONTRA: Computational ONcology TRaining Alliance Cancer is a major cause of death and suffering, rendering it a huge concern to the general public. Consequently, it has been targeted by app...
2017-08-31 - 2022-06-30 | Financiado

DRIVE: Driving next generation autophagy researchers towards translation INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-MSCA-ITN-2017 The manipulation of autophagy has an enormous therapeutic potential to revolutionize the way we currently treat cancers, neurodegenerative d...
2017-08-31 - 2022-04-30 | Financiado

ITCC-P4: ITCC Pediatric Preclinical POC Platform Sofia ref. 116064 INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant s...
2017-05-18 - 2023-12-31 | Financiado

REDOXCYCLE: The molecular interface between cell cycle and redox regulation INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG tramitó un H2020: ERC-2015-STG Aberrant cell cycle and redox regulation are hallmarks of cancer. While cell cycle and redox signaling are extensively studied, it remains p...
2016-01-25 - 2021-12-31 | Financiado

FORCE: Imaging the Force of Cancer INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-PHC-2014-2015 Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its...
2015-12-09 - 2021-07-31 | Financiado

Human Rpc5: RNA Polymerase III Rpc4 Rpc5 subcomplex and Selenocysteine tRNA transcription INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG tramitó un H2020: H2020-MSCA-IF-2014 In higher eukaryotes, the RNA polymerase III (Pol III) participates in the transcription of small RNAs such as the tRNAs. RNA polymerase rec...
2015-03-27 - 2017-04-30 | Financiado

EMCOP9CRL: Structural basis of Cullin RING ligase regulation by the COP9 signalosome INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG tramitó un H2020: H2020-MSCA-IF-2014 The components of the Cullin-RING Ligase (CRLs) E3 ubiquitin ligase family play key roles in a wide range of cellular processes including st...
2015-03-27 - 2017-10-11 | Financiado

B-CAST: Breast CAncer STratification understanding the determinants of risk and prognosis of molecular subt... INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER HOSPITAL LBG participó en un H2020: H2020-PHC-2014-2015 Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Throug...
2015-03-27 - 2021-02-28 | Financiado

ICR